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Stevenage, United KingdomBackground: Approximately 85% of nasal polyps (NPs) in white
subjects are characterized by prominent eosinophilia. IL-5 is the
key driver of eosinophilic differentiation and survival.
Objective: We sought to investigate the therapeutic potential of
inhibiting IL-5 with a humanized mAb as treatment for severe
nasal polyposis.
Methods: Thirty patients with severe nasal polyposis (grade 3 or 4
or recurrent after surgery) refractory to corticosteroid therapy
were randomized inadouble-blind fashion toreceive either2 single
intravenous injections (28 days apart) of 750 mg of mepolizumab
(n5 20) or placebo (n5 10). Change frombaseline inNPscorewas
assessed monthly until 1 month after the last dose (week 8).
Computed tomographic scans were also performed at week 8.
Results: Twelve of 20 patients receiving mepolizumab had a
significantly improved NP score and computed tomographic
scan score compared with 1 of 10 patients receiving placebo at
week 8 versus baseline.
Conclusion: Mepolizumab achieved a statistically significant
reduction in NP size for at least 1 month after dosing in 12 of 20
patients. IL-5 inhibition is a potential novel therapeutic
approach in patients with severe eosinophilic nasal polyposis.
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Chronic sinus disease covers a multitude of different entities,
such as chronic rhinosinusitis without nasal polyps (CRSsNP) and
chronic rhinosinusitis with nasal polyps (CRSwNP). Although in
the recent position paper for sinus disease of the European
Academy of Allergy and Clinical Immunology the difference
between CRSsNP and CRSwNP is made based on the results of
clinical investigation and endoscopy,1 other studies have sug-
gested that these 2 entities have distinct pathways of inflamma-
tion.2,3 CRSwNP in white patients is characterized by a TH2
eosinophilic inflammation with high levels of IL-5 and IgE,4-6
whereas CRSsNP shows a TH1 milieu with high IFN-g and
TGF-b1 concentrations.3
In white patients 80% to 90% of the nasal polyps (NPs) are
characterized by prominent eosinophilia.1,7 It is assumed that
through release of toxic products, eosinophils lead to tissue dam-
age and growth of polyps.8 The accumulation and activation of
eosinophils is favored by low concentrations of TGF-b1 and by
overproduction of IL-5 and eotaxin in NP tissue.3 High amounts
of IL-5 were detected in patients with NP, both at the mRNA and
protein levels.9,10 This cytokine seems to play a key role in the
chemotaxis, activation, and survival of eosinophils.11,12 Treat-
ment of eosinophil-infiltrated polyp tissue with neutralizing
anti–IL-5 mAb results in eosinophil apoptosis and decreases tis-
sue eosinophilia in vitro.10 Concerning the increased IgE level,
there is increasing evidence that Staphylococcus aureus–derived
enterotoxins stimulate eosinophilic inflammation through pro-
duction of TH2 cytokines and local IgE formation.
13
Interestingly, NPs of Chinese patients are clinically indistin-
guishable from polyps of their white counterparts, but they lack
IL-5 and eotaxin expression in the tissue, resulting in lower
numbers of tissue eosinophils.14,15 The direct comparisonof polyps
from Belgian and Chinese patients shows that there is a shared but
still to be clarified pathway ofmucosal edema formation,T-effector
cell activation, and regulatory T-cell impairment.16 Moreover,
white patients had comorbid asthma more frequently than Chinese
patients.16 Inflammation in asthmatic patients sharesmany features
with the eosinophilic inflammation seen in patients with NPs, such
as an increased number ofmucosal eosinophils, IgE formation, and
a TH2 profile with increased IL-5 and eotaxin levels.
17
These findings suggest that different types of polyps might
require different treatments based on the respective pathophys-
iology. Tailored medication schemes based on phenotyping have
to be developed. In white patients IL-5 is a key driver of989
TABLE I. Baseline characteristics of the study patients divided
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AC: Available case analysisBaseline characteristic group group value
AUC: Area under the curveCFB: Change from baseline
No. 20 10CRSsNP: Chronic rhinosinusitis without nasal polyps
Age (y), mean (SD) 50.05 (8.86) 45.9 (11.43) .37*CRSwNP: Chronic rhinosinusitis with nasal polyps
Female/male 6/14 2/8 .69CT: Computed tomography
Atopy (positive skin prick 10/20 4/10 .71ECP: Eosinophil cationic protein
test response)IL-5Ra: IL-5 receptor a subunitAsthma in history 10/20 3/10 .45LDL: Lower detection limit
Aspirin intolerance 5/20 0/10 .14LOCF: Last-observation-carried-forward imputation
Sinus surgery in history 15/20 8/10 1.00MPO: Myeloperoxidase
Duration of disease (y), 10.5 (5.61) 14.3 (8.23) .25*NP: Nasal polyp
mean (SD)nPIF: Nasal peak inspiratory flowTobacco use 5/20 1/10 .64TPS: Total polyp score
TPS, mean (SD) 5.2 (1.74) 5.5 (1.65) .70*
Total symptom score, mean (SD) 7.95 (1.79) 8.4 (1.71) .48*
Loss of smell, mean (SD) 2.65 (0.59) 2.4 (0.84) .50*
Congestion, mean (SD) 2.15 (0.75) 2.4 (0.70) .41*
Anterior rhinorrhea, mean (SD) 1.5 (0.89) 1.8 (0.79) .49*
Postnasal drip, mean (SD) 1.65 (0.99) 1.8 (0.63) .77*
*Exact Mann-Whitney U test.
Fisher exact test.maintaining polyps, namely eosinophilic differentiation and
survival. The objective of the current study was to investigate
the therapeutic potential of inhibiting IL-5 by using a humanized
mAb as treatment for severe nasal polyposis. Our group has been
able to demonstrate shrinkage of NPs in more than half of the
patients treated with a single intravenous injection of an anti-
human IL-5 mAb in the past.18 Moreover, local IL-5 concentra-
tions at baseline were significantly higher in responders in
contrast to those seen in nonresponders. We suggested that nasal
IL-5 levels could predict the response to anti–IL-5 treatment.18
However, the primary end point of this study was safety, and
efficacywas only studied bymeans of nasal endoscopy. In the cur-
rent study we wanted to determine the efficacy of 2 injections of
mepolizumab on NP volume in patients with severe CRSwNP
using nasal endoscopy and computed tomographic (CT) scan
imaging. In addition, markers of biological activity, such as
IL-5 levels and nasal eosinophilia, were assessed over a period
of 11 months after the last dose.METHODS
Patients
Thirty subjects with chronic rhinosinusitis with primary NPs (grade 3 or 4,
see outcomemeasures) or NPs that are recurrent after surgery (grade 1-4) were
included. The inclusion criteria specified that subjects must have had failure of
standard care forCRSwNP, and the diagnosis of this conditionwas based on the
European position paper on rhinosinusitis and NPs.1 Use of systemic cortico-
steroids and surgical intervention was not allowed from 1 month before treat-
ment until the end of the study, and subjects were not permitted to use nasal
corticosteroids, nasal antihistamines, nasal atropine, nasal cromolyn, nasal
saline, or antibiotic treatment for 2 months after first dosing. The study was
conducted at the Department of Otorhinolaryngology of the University Hospi-
tal in Ghent, Belgium. The local ethics committee approved the study, and all
volunteers providedwritten informed consent before participation in the study.Study design
We performed a randomized, double-blind, placebo-controlled study of
mepolizumab in patients with CRSwNP. After signing the informed consent
form and a 4- to 12-week run-in period, subjects were randomized to receive 2
single intravenous injections (28 days apart) of 750 mg of mepolizumab (20
subjects) or placebo (10 subjects). Follow-up visits were scheduled 1, 4, 8, 12,
24, 36, and 48 weeks after first dosing. During the follow-up visit after 4
weeks, the second injection of mepolizumab was administered (see Fig E1 in
this article’s Online Repository at www.jacionline.org). All randomized
patients were included in the analysis. The study was double blind up to
48 weeks.Outcome measures
The primary end point of this study was the reduction in NP score19,20 at 8
weeks after the first dosing (1 month after the second dose). This total polyp
score (TPS) is the sum of the right and left nostril scores, as evaluated by
means of nasal endoscopy. CRSwNP was graded based on polyp size: 0, no
polyps; 1, small polyps in the middle meatus not reaching below the inferior
border of the middle concha; 2, polyps reaching below the lower border of the
middle turbinate; 3, large polyps reaching the lower border of the inferior
turbinate or polyps medial to the middle concha; and 4, large polyps causing
complete obstruction of the inferior meatus.
Secondary end points included changes in CT scan scores and assessments,
such as nasal peak inspiratory flow (nPIF) or symptom score (sum of
individual symptoms: anterior rhinorrhea, nasal obstruction, postnasal drip,
and loss of sense of smell; 0, no symptoms; 1, mild symptoms; 2, moderate
symptoms; and 3, severe symptoms). CT scanswere assessed for improvement
versus worsening or no change after 8 weeks with respect to baseline values.
This was done independently by 3 different observers. Biological activity was
evaluated based on peripheral blood eosinophil counts and measurement of
cytokines and mediators in sera and nasal secretions. Blood eosinophils were
counted automatically by using a 2-mL heparinized blood sample. Nasal
secretions were obtained by placing sinus packs (IVALON 4000 plus) in both
nasal cavities for exactly 5 minutes, which were immediately processed as
previously described.12 Serum and nasal secretions were assayed by means of
ELISA for IL-1b, IL-5 (R&DSystems,Minneapolis, Minn), myeloperoxidase
(MPO; BioCheck, Foster City, Calif), and soluble IL-5 receptor a subunit
(IL-5Ra; Innogenetics, Ghent, Belgium). Eosinophil cationic protein (ECP)
concentrations were obtained by using the UniCAP system (Pharmacia &
Upjohn, Uppsala, Sweden), whereas IL-6 concentrations were measured
with a Fluorokine MAP cytokine multiplex kit (R&D Systems) using the
Bio-Rad Bio-plex 200 (Bio-Rad Laboratories, Hercules, Calif). The lower
detection limits (LDLs) before dilution were 2 mg/L for nasal ECP, 3.9 pg/
mL for nasal IL-5, 7.8 pg/mL for nasal IL-5Ra, 1.8 pg/mL for nasal IL-6,
0.2 kU/L for nasal total IgE, and 0.1 kU/L for serum total IgE.
Safety was assessed based on adverse event reporting, vital signs mea-
surement, symptom checks, physical examination, and blood analysis.Statistical analysis
The primary end point of this study was the change from baseline (CFB) in
TPS at week 8. This was analyzed by using the exactMann-WhitneyU test. As
FIG 1. A, Mean CFB in TPS based on LOCF for the treated (solid line) and placebo (dashed line) groups
starting at the moment of first administration. Error bars indicate 95% CIs of the mean based on normal
approximation. B, Baseline and week 8 TPSs in absolute values based on LOCF for each subject and divided
into the mepolizumab-treated and placebo groups.
J ALLERGY CLIN IMMUNOL
VOLUME 128, NUMBER 5
GEVAERT ET AL 991a supporting analysis, improvement in TPS (defined as a negative CFB) was
analyzed by using the Fisher exact test. Because of the large number of drop-
outs, we did not interpret any observations after week 8.
Regarding the CT scans, we checked interrater reliability by using the
Fleiss k coefficient. The Fisher exact test of CT score improvement in the
treated versus placebo groups was performed for each rater. Symptom scores,
blood eosinophil counts, serum ECP levels, and serum IL-5Ra levels were
analyzed by using the exact Mann-Whitney U test, and nPIF was analyzed by
using the area under the curve (AUC). For the markers in nasal secretions,
there were a lot of observations below the LDL. Because of this, the Peto-
Peto-Prentice test was used because it uses all data, acknowledging the unob-
served values of less than the LDL, without imputing an exact value for
them.21 For nasal MPO levels, there was no LDL issue, and we have tested
its CFB by using the exact Mann-Whitney U test.
Because of the large number of dropouts, the time to withdrawal was
compared by using a Kaplan-Meier plot and the log-rank test. We also looked
at the reasons for dropout and their implications in more detail. To deal with
the missing data problem, we performed a last-observation-carried-forward
imputation (LOCF) and an available case analysis (AC). Concerns exist
regarding whether it is appropriate to use LOCF or AC.22 For brevity, through-
out the article, only the LOCF results are stated, but the AC results are also
calculated (see Table E1 in this article’s Online Repository at www.
jacionline.org).
Within the treated group, a distinction could be made between responders
(persons with an improved TPS of >_1 unit at week 8 vs baseline values) and
nonresponders. We investigated whether there were baseline differences
between responders and nonresponders, again using the exact Mann-Whitney
U test and the Peto-Peto-Prentice test, where appropriate.
We performed a post hoc power calculation for theMann-WhitneyU test of
the primary end point (ie, TPSCFB at week 8) based on the present study using
the O’Brien-Castelloe approximation. A post hoc power of 68% was obtained
by using the LOCF paradigm.
Data analysis was performed with SAS version 9.1 software (http://www.
sas.com/; SAS Institute, Inc, Cary, NC) and R version 2.11.1 software
(http://cran.r-project.org/). Error bars in the figures represent 95% CIs of the
mean based on normal approximation.RESULTS
Patients
The baseline characteristics of the study patients are summa-
rized in Table I. The history and symptoms of the mepolizumaband placebo groups were compared. Age and sex were similar.
Almost half of the patients were atopic (based on skin prick test
responses), and 43% had asthma. The number of patients who
had undergone sinus surgery in the past was high. At baseline,
our patient population consisted of 3 patients with grade 1, 6 pa-
tients with grade 2, 16 patients with grade 3, and 5 patients with
grade 4maximal unilateral NP size equally divided into the differ-
ent groups. Consequently, the mean TPS in both groups was
comparable.Safety and adverse events
Sixteen (53%) of the 30 subjects reported at least 1 adverse
event over 48 weeks of follow-up. One serious adverse event and
23 adverse events occurred. The serious adverse event was a
diverticulitis caused by a preexisting condition and not considered
to be related to the study drug. Of the adverse events, the common
coldwas themost frequent, as reported by 6 persons (5 episodes in
themepolizumab-treated group and 1 in the placebo group). Table
E2 in this article’s Online Repository at www.jacionline.org
shows all the adverse events, comparing the mepolizumab-
treated patients with the placebo group. None of them reached
significance. We observed no meaningful changes in vital signs,
physical examination results, and blood analysis.Primary end point: TPS
The primary end point was the difference in TPS at week 8
(visit 5) versus baseline (visit 2). By using LOCF, the CFB with
mepolizumab was 21.30 (SD, 1.72), and that with placebo was
0.00 (SD, 0.94), resulting in a treatment difference of21.30 (SD,
1.51; P 5 .028, Mann-Whitney U test). Fig 1 shows the CFB at
different time points and the baseline and week 8 TPSs for each
subject.
Again, by using LOCF, the percentage improvement in TPS for
mepolizumab was greater than that with placebo at 60% versus
10% (odds ratio, 13.5; P 5 .018, Fisher exact test).
Table E1 shows an overview of results obtained by using the
LOCF and AC paradigms in the presence of missing data for
FIG 2. Mean CFB in serum ECP levels, blood eosinophil counts, serum IL-5Ra levels, and nasal MPO levels
andmean nasal IL-1b and IL-5Ra levels (all in micrograms per liter), imputing 0 for observations of less than
the LDL. These representations are based on LOCF and show the mepolizumab-treated (solid line) and
placebo (dashed line) groups starting at the moment of first administration. Error bars indicate 95% CIs
of the mean based on normal approximation.
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provement. The LOCF and AC values of the comparisons below
are also mentioned.CT score improvement
The Fleiss k coefficient of interrater reliability was 0.679 by
using LOCF, indicating good agreement among the 3 raters of the
FIG 3. Proportion of patients still in the study in the mepolizumab-treated
(solid line) and placebo (dashed line) groups starting at the moment of first
administration.
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jacionline.org shows the percentage improvement in CT scan
scores. An improvement was seen in more than half of the
mepolizumab-treated patients and less than 20% of the placebo
group compared with the baseline scans (P 5 .058, P 5 .024,
and P5 .049 for the different raters by using LOCF, Fisher exact
test).Symptom scores and nPIF
Reduction from baseline in loss of smell, postnasal drip, and
congestion at week 8 was greater in the treated group than in the
placebo group, but rhinorrhea stayed at the same level. Remark-
ably, the improvement in loss of smell stayed at the same level
during the whole period of follow-up (11 months after the last
dose), whereas the other symptoms normalized after a period of
time. However, none of these differences were statistically
significant. Fig E3 in this article’s Online Repository at www.
jacionline.org shows the mean CFB in nPIF, resulting in a differ-
ent AUC. This suggests better values of nPIF in themepolizumab-
treated group than in the placebo group. The nPIF AUC values
were also formally compared, resulting in a P value of .095 for
LOCF.Blood and serum markers
The CFB at week 8 in blood eosinophil counts (P < .001 for
LOCF), serum ECP levels (P 5 .022 for LOCF), and serum IL-
5Ra levels (P < .001 for LOCF) showed a significant reduction
in the mepolizumab-treated versus placebo group. Evolution of
serum ECP levels, blood eosinophil counts, and serum IL-5Ra
levels is shown in Fig 2, whereas the individual values of week
0 and 8 are shown in Fig E4 in this article’s Online Repository
at www.jacionline.org.Markers in nasal secretion
In contrast with nasal ECP (P5 .260 using LOCF), nasal IL-5
(P 5 .094 using LOCF), and nasal total IgE (P 5 .170 usingLOCF) levels at week 8, which were not significantly different
between groups, nasal IL-5Ra (P 5 .010 for LOCF), nasal IL-6
(P5 .020 for LOCF), and nasal IL-1b (P5 .043 for LOCF) levels
were significantly lower in the treated group. The CFB at week 8
in nasal MPO levels (P5 .008 using LOCF) showed a significant
reduction in the mepolizumab-treated group. Evolution of nasal
IL-1b, IL-5Ra, and MPO levels is also shown in Fig 2, whereas
the individual values of MPO are provided in Fig E4 as well.Dropouts
The proportions of treated patients and patients receiving
placebo still in the study at the different time points can be seen in
Fig 3. There were 3 dropouts at the time of the primary end point
(week 8), all of them in the placebo group. At the end of the study,
there was a considerable dropout rate in both the mepolizumab
and placebo arms. However, the time to dropout was significantly
longer in the mepolizumab arm (P 5 .005, log-rank test vs pla-
cebo). The reasons for dropout were comparable (Table II). The
most important were the need for rescue medication (5/20 in
the mepolizumab-treated group and 3/10 in the placebo group)
and nasal surgery with removal of NPs (4/20 in the
mepolizumab-treated group and 3/10 in the placebo group),
which were said to be exclusion criteria.Responder analysis
The percentage of patients responding with an improvement in
TPS at week 8 was 60% in the mepolizumab group (see Fig E5 in
this article’s Online Repository at www.jacionline.org). None of
the baseline characteristics was significantly different between re-
sponders and nonresponders. In particular, we found no difference
for baseline TPSs and local IL-5 levels (P 5 .97 and P 5 .26).DISCUSSION
In this double-blind, randomized, placebo-controlled study we
evaluated the effect of 2 intravenous injections of 750 mg of
mepolizumab in patients with severe CRSwNP. This treatment
produced a significant reduction in TPSs in 12 of 20 patients.
These effects were confirmed by changes in CT scan evaluations.
Together, the observations support a role for anti–IL-5 in a
subgroup of patients with CRSwNP and confirm previous results
achieved with a single injection of a different anti–IL-5 antibody,
reslizumab.18 It is possible that additional doses of mepolizumab
could lead to a larger effect on nasal polyposis or even resolution
of the disease in a still undefined subpopulation of patients with
polyps. Moreover, the rebound eosinophilia seen with reslizumab
was not observed with mepolizumab.
As previous studies showed, anti–IL-5 treatment is safe and
well tolerated.18,23,24 In our study we did not observe significant
differences in adverse events between the treatment and placebo
groups.
Both groups had a mean TPS of between 5 and 6 of a potential
maximum of 8 points at baseline, reflecting the severity of the
disease as determined by the inclusion criteria. A higher propor-
tion of patients in the treated group improved compared with
those in the placebo group at week 4, and this number increased
after the second dosing. A beneficial effect was seen in more than
half of the treated patients 1 month after the last dose. Because
similar studies with anti–IL-5 treatment are lacking, we could
TABLE II. Overview of reasons for dropout in the mepolizumab-treated and placebo groups
Week 8 (primary time point) Week 48 (end of study)
Mepolizumab-treated group Placebo group Mepolizumab-treated group Placebo group
Still in study 20/20 7/10 9/20 1/10
Rescue operation 0/20 1/10 4/20 3/10
Rescue medication 0/20 1/10 5/20 3/10
Accidental medication 0/20 1/10 1/20 1/10
Did not show up 0/20 0/10 1/20 2/10
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also showed a reduction in NP size in half of the patients. A meta-
analysis testing the effect of intranasal steroids compared with
placebo found a decrease in NP assessment (score of 0-3, which
is comparable with our TPS without grade 4) of 0.43 to 0.63,25
and we observed a mean decrease of 1.30 (with 4 grades instead
of 3) with mepolizumab.
Of importance, the changes in the TPS were assessed objec-
tively by using repetitive CT scans and evaluated by 3 indepen-
dent observers. CT scan imaging confirmed that more than half of
the patients objectively profited from this potentially new ther-
apeutic approach.
The typical symptoms that are so characteristic of CRSwNP all
showed trends toward improvement in the treated group, except
rhinorrhea, but none of them reached statistical significance.
Some of the effects were long lasting; the reduction in loss of
smell in the treated group lasted for thewhole period of follow-up.
Nasal congestion seemed to improve temporarily, without reach-
ing significance. Furthermore, nPIF changes compared with
baseline values were superior in the mepolizumab-treated group,
suggesting a decrease in nasal obstruction.
When analyzing systemic and local markers of eosinophilic
inflammation, we found a significant decrease in blood eosinophil
counts in the treated group compared with the placebo group,
which was also reflected by ECP levels in sera. This is in line with
the results of other studies in asthmatic patients and is considered
the most important effect of the treatment in patients with
hypereosinophilic syndrome.26-28 The decrease in blood eosino-
phil counts was paralleled by a decrease in serum and nasal secre-
tion IL-5Ra concentrations. Furthermore, nasal IL-6, MPO, and
IL-1b levels were significantly decreased, suggesting effects of
treatment also on the parameters of the neutrophilic inflammation
present in patients with CRSwNP.
In contrast to reslizumab, there was no reactive eosinophilia
with mepolizumab; this counterregulation clearly was of concern
in former studies.18,23 However, increasing blood eosinophil
counts with associated deterioration of the clinical condition is
also reported with mepolizumab.29 The rebound eosinophilia af-
ter anti–IL-5 treatment is a result of a serum factor that enhances
eosinophil survival. Reversal of this effect by the addition of anti–
IL-5 suggests that this factor might be IL-5 itself.30 We suggest
that rebound eosinophilia could be avoided by the administration
of multiple doses of anti–IL-5 treatment. This effect has also been
seen in studies with more than 1 injection.23,28,29 Monthly admin-
istration of this treatment is supposed to be most appropriate,
stabilizing the clinical course and preventing rebound eosino-
philia.29 However, one study found that improvement in symp-
toms and eosinophilia lessened with each subsequent dose.23 It
remains unclear whether prolonged treatment with anti–IL-5
could be used and what the effect would be.Because these patients have severe and disabling disease, we
observed clearly more dropouts in the course of the study in the
placebo group compared with the treatment group. Fig 3 shows
that, at any point, the dropout rate was larger in the placebo group
than in the mepolizumab-treated group. This difference was sig-
nificant, indicating that dropout depends on treatment. In fact,
themain reasons for exclusion were the need for systemic steroids
and the need for surgery in the follow-up period, both of which
were greater in the placebo group, although each reason for drop-
out was not statistically significant.
The comparison between responders and nonresponders did
not provide the expected proof of the relationship between
response to treatment and concentrations of IL-5 in nasal secre-
tions at baseline, as seen in our previous study.18 We also tested
the effect of mepolizumab in the responder group (see the
Methods and Results sections and Fig E5 in this article’s Online
Repository at www.jacionline.org). The decrease in TPSs in
responders was significantly maintained until 36 weeks after
treatment, implying a long-term effect.
One of the major study limitations is the small sample size (n5
30). This is probably the reason why we did not observe
significant changes in symptom scores, although the NP and CT
scan scores significantly improved. Another study limitation is
the long-term dropout rate, which makes interpretation of long-
term follow-up data difficult. Moreover, we only tested the
administration of 2 injections of mepolizumab. More studies
with a larger sample size and long-term treatment are required to
determine the optimal treatment scheme for clinical use. Atten-
tion should be paid to parameters predicting treatment success
because this will be of clinical relevance. We believe that anti–
IL-5 treatment has great potential, especially when we succeed in
predicting the patients who would respond to treatment.
In summary, 2 injections of 750 mg of anti–IL-5 mAb
(mepolizumab) showed a significant improvement over placebo
in the endoscopic TPS. The TPS was decreased at week 8 in 12
of 20 patients receiving mepolizumab in contrast to 1 of 10
patients receiving placebo. In addition, 11 of 20 mepolizumab-
treated patients showed an improvement in CT scan scores.
Furthermore, the injection of 2 doses of mepolizumab was well
tolerated, and no rebound eosinophilia was observed. IL-5
inhibition seems to be a promising novel therapeutic approach
in patients with severe CRSwNP, but we require more long-term
studies to assess its full possibilities and indications. Better
phenotyping could help to select the patients who would benefit
from this treatment.Clinical implications: Two intravenous injections with mepoli-
zumab (anti–IL-5) significantly reduce the size of NPs based
on endoscopic scoring and blinded CT scan assessment.
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A distinction was made between responders (persons with an improved
TPS of >_1 unit at week 8 vs baseline) and nonresponders within the treated
group to investigate whether there were baseline differences between them.
We kept the same classification to estimate the long-term effect of the
treatment. Because there were fewer dropouts in the responder group, we
could reliably interpret results up to week 36. We tested for a significant CFB
in TPSs within the responders at different time points using the exact
Wilcoxon signed-rank test. This test was also performed on the CFB of the
symptom scores at week 8 within responders.
RESULTS
The percentage of patients responding with an improvement
in TPS at week 8 was 60% in the mepolizumab-treated group.At week 36, 9 of 12 responders and 2 of 8 nonresponders were
still in the study (P 5 .045, log-rank test of dropout responders
vs nonresponders). Among the responders, the CFB in TPS was
significantly different from 0 up to week 36. The CFB in TPS
for responders and nonresponders is depicted in Fig E5. The
CFB in symptom scores at week 8 among responders was sig-
nificantly different from 0. In particular, we found a significant
decrease at week 8 versus baseline for congestion (P 5 .001),
rhinorrhea (P 5 .012), and postnasal drip (P 5 .020), whereas
loss of smell was also reduced but did not reach significance
(P 5 .079).
FIG E1. Study outline showing the different patient visits and the respective
investigations.
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FIG E2. Proportional improvement in CT scan scores based on LOCF for the
mepolizumab-treated (black columns) and placebo (gray columns) groups
rated by 3 different observers (A, B, and C). Error bars indicate 95% CIs of
the proportion based on normal approximation.
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FIG E3. Mean CFB in nPIF based on LOCF for the treated (solid line) and pla-
cebo (dashed line) groups starting at the moment of first administration.
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FIG E4. Individual values of serum ECP levels, blood eosinophil counts, serum IL-5Ra levels, and nasal MPO
levels (all in micrograms per liter) at weeks 0 and 8 based on LOCF for themepolizumab-treated and placebo
groups.
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FIG E5. Mean CFB in TPS based on LOCF for responders (solid line) and
nonresponders (dashed line) starting at the moment of first administration.
Error bars indicate 95% CIs of the mean based on normal approximation.
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TABLE E1. Comparison of results obtained by using the LOCF and AC paradigms in the presence of missing data
Quantity
LOCF paradigm AC paradigm
Effect size P value Effect size P value
TPS CFB at week 8* 21.3 (1.51) .028 21.3 (1.50) .037
Power for TPS CFB at week 8 0.68 — 0.66 —
TPS improvement vs baseline at week 8 13.50 .018 26.05 .009
CT improvement, interrater reliability§ 0.68 — 0.65 —
CT improvement, rater A 6.00 .06 3.75 .21
CT improvement, rater B 11.00 .024 7.33 .10
CT improvement, rater C 9.00 .049 6.00 .19
nPIF AUC* 1,047 (1,602) .10 NA# NA#
Blood eosinophil count, CFB at week 8* 2332 (241) <.001 2413 (213) <.001
Serum ECP level, CFB at week 8* 22,124 (2,514) .022 22,425 (2,622) .025
Serum IL-5Ra level, CFB at week 8* 29,255 (7,520) <.001 29,829 (7,913) <.001
Nasal ECP level at week 8{ 0.77 .26 0.82 .42
Nasal IL-5 level at week 8{ 0.39 .10 0.50 .31
Nasal total IgE level at week 8{ 0.61 .17 0.60 .23
Nasal IL-5Ra level at week 8{ 0.30 .010 0.38 .06
Nasal IL-6 level at week 8{ 0.44 .020 0.32 .026
Nasal IL-1b level at week 8{ 0.45 .043 0.38 .038
Nasal MPO level, CFB at week 8* 211,891 (11,150) .009 212,970 (12,102) .041
TPS, CFB within responders at week 24k 21.67 (1.44) .006 22.33 (1.30) <.001
TPS, CFB within responders at week 36k 20.92 (1.24) .047 21.89 (1.62) .024
*Values are presented as means (SDs), according to the exact Mann-Whitney U test.
O’Brien-Castelloe approximation of post hoc power of Mann-Whitney U test.
Odds ratio, Fisher exact test.
§Fleiss k coefficient.
{Hazard ratio, Peto-Peto-Prentice test.
kValues are presented as means (SDs), exact Wilcoxon signed-rank test.
#Not possible because of small sample remaining.
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TABLE E2. Comparison of reported serious adverse events and
adverse events between the mepolizumab-treated and placebo
groups
Mepolizumab-treated
group (n 5 20)
Placebo
group (n 5 10)
Serious adverse events:
diverticulitis (preexisting) 1 0
Adverse events:
Allergic reaction:
amoxicillin–clavulanic acid
1 0
Allergic reaction: mosquito 1 0
Bronchitis 3 0
Common cold 5 1
Disc herniation (preexisting) 1 0
Fracture (arm) 1 0
Headache (3 d after injection) 1 0
Mild increased thyroid hormones
(T3 and T4)
1 0
Otitis 1 0
Pain on 3 left fingers
(nervus medianus)
1 0
Pharyngitis 1 0
Red swollen eyes 0 1
Short of breath 1 0
Sinusitis 2 1
Each number represents how many episodes of the event occurred in the respective
group.
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